Healthcare providers should establish clear communication channels for patients to report concerns and should conduct regular follow-up assessments, particularly during dose titration periods when adverse effects are most likely to emerge
However, patients should be advised to report symptoms suggestive of liver injury, including: Persistent nausea or vomiting unrelated to expected GI side effects Right upper quadrant abdominal pain (which may also indicate gallbladder disease, a known risk with GLP-1 therapy) Jaundice (yellowing of skin or eyes) Dark urine or pale stools Unexplained fatigue or malaise Clinicians should maintain a low threshold for investigating these symptoms with comprehensive liver function tests, including ALT, AST, alkaline phosphatase, bilirubin, albumin, and INR/prothrombin time
One to two minutes at room temperature is sufficient
Management of kidney disease is vital to overall health and quality of life
The semaglutide units to mg conversion changes based on this concentration, and ignoring it leads to dosing errors that can produce either underwhelming results or overwhelming side effects
